The FERWON‐NEPHRO study enrolled adults (≥18 years) with Hb ≤11 g/dL, s‐ferritin ≤100 ng/mL (≤300 ng/mL if TSAT ≤30%), CKD defined as either an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 at screening or eGFR <90 mL/min/1.73 m2 at screening and kidney damage as indicated by abnormalities in urine composition per medical history and/or intermediate/high risk of cardiovascular disease according to the Framingham model24 and either not taking erythropoietin‐stimulating agents or on a stable dose for 4 weeks prior to randomization. This evidence concerns the gene EPO and chronic kidney disease.